Aims
To elucidate the diagnostic value of sarcoplasmic expression of myxovirus resistance protein A (MxA) for dermatomyositis (DM) specifically analysing different DM subforms, and to test the superiority of MxA to other markers.
Methods
Immunohistochemistry for MxA and retinoic acid‐inducible gene I (RIG‐I) was performed on skeletal muscle samples and compared with the item presence of perifascicular atrophy (PFA) in 57 DM patients with anti‐Mi‐2 (n = 6), ‐transcription intermediary factor 1 gamma (n = 10), ‐nuclear matrix protein 2 (n = 13), ‐melanoma differentiation‐associated gene 5 (MDA5) (n = 10) or ‐small ubiquitin‐like modifier activating enzyme (n = 1) autoantibodies and with no detectable autoantibody (n = 17). Among the patients, nine suffered from cancer and 22 were juvenile‐onset type. Disease controls included antisynthetase syndrome (ASS)‐associated myositis (n = 30), immune‐mediated necrotizing myopathy (n = 9) and inclusion body myositis (n = 5).
Results
Sarcoplasmic MxA expression featured 77% sensitivity and 100% specificity for overall DM patients, while RIG‐I staining and PFA reached respectively 14% and 59% sensitivity and 100% and 86% specificity. In any subset of DM, sarcoplasmic MxA expression showed higher sensitivity than RIG‐I and PFA. Some anti‐MDA5 antibody‐positive DM samples distinctively showed a scattered staining pattern of MxA. No ASS samples had sarcoplasmic MxA expression even though six patients had DM skin rash.
Conclusions
Sarcoplasmic MxA expression is more sensitive than PFA and RIG‐I expression for a pathological diagnosis of DM, regardless of the autoantibody‐related subgroup. In light of its high sensitivity and specificity, it may be considered a pathological hallmark of DM per se. Also, lack of MxA expression in ASS supports the idea that ASS is a distinct entity from DM.